JP2013543114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543114A5 JP2013543114A5 JP2013528375A JP2013528375A JP2013543114A5 JP 2013543114 A5 JP2013543114 A5 JP 2013543114A5 JP 2013528375 A JP2013528375 A JP 2013528375A JP 2013528375 A JP2013528375 A JP 2013528375A JP 2013543114 A5 JP2013543114 A5 JP 2013543114A5
- Authority
- JP
- Japan
- Prior art keywords
- ezh2
- mutation
- pharmaceutical composition
- subject
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38168410P | 2010-09-10 | 2010-09-10 | |
| US61/381,684 | 2010-09-10 | ||
| PCT/US2011/051258 WO2012034132A2 (en) | 2010-09-10 | 2011-09-12 | Inhibitors of human ezh2, and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016221254A Division JP6496296B2 (ja) | 2010-09-10 | 2016-11-14 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543114A JP2013543114A (ja) | 2013-11-28 |
| JP2013543114A5 true JP2013543114A5 (enExample) | 2015-05-07 |
| JP6389036B2 JP6389036B2 (ja) | 2018-09-12 |
Family
ID=45811204
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013528375A Active JP6389036B2 (ja) | 2010-09-10 | 2011-09-12 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2016221254A Active JP6496296B2 (ja) | 2010-09-10 | 2016-11-14 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2018218823A Pending JP2019070653A (ja) | 2010-09-10 | 2018-11-22 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2021096308A Pending JP2021169450A (ja) | 2010-09-10 | 2021-06-09 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2023127439A Pending JP2023153949A (ja) | 2010-09-10 | 2023-08-04 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016221254A Active JP6496296B2 (ja) | 2010-09-10 | 2016-11-14 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2018218823A Pending JP2019070653A (ja) | 2010-09-10 | 2018-11-22 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2021096308A Pending JP2021169450A (ja) | 2010-09-10 | 2021-06-09 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
| JP2023127439A Pending JP2023153949A (ja) | 2010-09-10 | 2023-08-04 | ヒトｅｚｈ２の阻害剤、およびその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US8895245B2 (enExample) |
| EP (1) | EP2614369B2 (enExample) |
| JP (5) | JP6389036B2 (enExample) |
| KR (3) | KR102061353B1 (enExample) |
| CN (2) | CN105797158B (enExample) |
| AU (4) | AU2011298987B2 (enExample) |
| BR (1) | BR112013005806B1 (enExample) |
| CA (2) | CA2810998C (enExample) |
| DK (1) | DK2614369T3 (enExample) |
| ES (1) | ES2570380T3 (enExample) |
| HU (1) | HUE028977T2 (enExample) |
| PL (1) | PL2614369T3 (enExample) |
| RU (2) | RU2765155C2 (enExample) |
| WO (1) | WO2012034132A2 (enExample) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112014007603A2 (pt) * | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| IN2014DN07812A (enExample) | 2012-02-27 | 2015-05-15 | British Columbia Cancer Agency | |
| HUE042271T2 (hu) * | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| KR102117982B1 (ko) | 2012-04-13 | 2020-06-03 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
| DK3628670T3 (da) | 2012-04-13 | 2022-12-05 | Epizyme Inc | Saltform til ezh2-hæmning |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| JP2015523853A (ja) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Ａｔｐ２ａ２発現を調節するための組成物及び方法 |
| SG11201407486PA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating utrn expression |
| KR20150030205A (ko) | 2012-05-16 | 2015-03-19 | 라나 테라퓨틱스, 인크. | Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법 |
| EA201492121A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии семейства генов гемоглобина |
| KR102021642B1 (ko) * | 2012-10-15 | 2019-09-16 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| CN105102432B (zh) | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| EP2914298B1 (en) | 2012-11-02 | 2020-01-08 | Duke University | Inhibition of histone methyltransferase for cardiac reprogramming |
| SG11201503893RA (en) | 2012-11-19 | 2015-06-29 | Agency Science Tech & Res | Method of treating cancer |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| AU2013361079B2 (en) * | 2012-12-21 | 2018-07-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| WO2014153226A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム，インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
| US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| EP2970131B1 (en) | 2013-03-14 | 2017-11-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
| KR20150127216A (ko) | 2013-03-14 | 2015-11-16 | 제넨테크, 인크. | 암의 치료 및 암 약물 내성의 예방 방법 |
| EP2970136A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyl transferase inhibtors and uses thereof |
| US9394258B2 (en) | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970181B1 (en) | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20160024051A1 (en) | 2013-03-15 | 2016-01-28 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| US20160091485A1 (en) * | 2013-04-25 | 2016-03-31 | The Broad Institute, Inc. | Markers for ezh2 inhibitors |
| ES2834638T3 (es) | 2013-05-30 | 2021-06-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa |
| WO2014197826A1 (en) * | 2013-06-07 | 2014-12-11 | Rana Therapeutics, Inc. | Compositions and methods for modulating foxp3 expression |
| US9828393B2 (en) * | 2013-07-22 | 2017-11-28 | The Regents Of The University Of Colorado, A Body Corporate | Silylalkyloxyaryl compounds and methods for treating cancer |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3057962B1 (en) | 2013-10-16 | 2023-10-18 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| WO2015061204A1 (en) | 2013-10-21 | 2015-04-30 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3076977B1 (en) | 2013-12-06 | 2021-03-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| US20150320754A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US10603295B2 (en) | 2014-04-28 | 2020-03-31 | Massachusetts Eye And Ear Infirmary | Sensorineural hair cell differentiation |
| AP2016009605A0 (en) | 2014-06-17 | 2016-12-31 | Pfizer | Substituted dihydroisoquinolinone compounds |
| BR112016029492A2 (pt) * | 2014-06-17 | 2017-10-17 | Eisai R&D Man Co Ltd | método para tratamento de linfoma não hodgkin |
| CA2952285A1 (en) | 2014-06-19 | 2015-12-23 | Memorial Sloan-Kettering Cancer Center | Biomarkers for response to ezh2 inhibitors |
| JP2016044993A (ja) * | 2014-08-20 | 2016-04-04 | 有限会社マイテック | ヒストン化学修飾判定による癌診断方法 |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| MX383635B (es) * | 2014-10-16 | 2025-03-14 | Epizyme Inc | Método para tratar el cáncer. |
| WO2016073956A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Ezh2 inhibitors and uses thereof |
| SG11201703806XA (en) | 2014-11-17 | 2017-06-29 | Epizyme Inc | Method for treating cancer |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CN107108637B (zh) | 2014-12-23 | 2019-10-29 | 诺华股份有限公司 | 三唑并嘧啶化合物及其用途 |
| EP3236962A2 (en) | 2014-12-23 | 2017-11-01 | University of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
| EA201792304A1 (ru) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| AU2016275051A1 (en) | 2015-06-10 | 2017-12-07 | Epizyme, Inc. | EZH2 inhibitors for treating lymphoma |
| JP2018522045A (ja) * | 2015-08-03 | 2018-08-09 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Ｅｚｈ２阻害剤および制御性ｔ細胞機能の調節 |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| MX2018003663A (es) * | 2015-09-25 | 2018-08-14 | Epizyme Inc | Metodo de tratamiento de tumor rabdoide maligno del ovario (mrto) /cancer microcitico del ovario del tipo hipercalcemico (sccoht) con un inhibidor de ezh2. |
| US12318489B2 (en) | 2015-10-26 | 2025-06-03 | Translate Bio Ma, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
| JP2019500623A (ja) | 2015-11-05 | 2019-01-10 | エピザイム，インコーポレイティド | ヒストンｈ３メチル化ステータスをモニターするためのフローサイトメトリー |
| WO2017132518A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
| GB201700138D0 (en) | 2017-01-05 | 2017-02-22 | Senzagen Ab | Analytical methods and arrays for use in the same |
| EP3445365A4 (en) * | 2016-04-22 | 2019-10-16 | Dana-Farber Cancer Institute, Inc. | EZH2 INHIBITORS AND USES THEREOF |
| CN105777718B (zh) * | 2016-04-27 | 2019-03-19 | 上海应用技术学院 | 潜在ezh2小分子抑制剂及其合成方法 |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| US10676479B2 (en) | 2016-06-20 | 2020-06-09 | Novartis Ag | Imidazolepyridine compounds and uses thereof |
| IL263429B (en) | 2016-06-20 | 2022-08-01 | Novartis Ag | Crystalline forms of triazolopyrimidine compound |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| EP3548032A2 (en) * | 2016-12-02 | 2019-10-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| WO2018223030A1 (en) | 2017-06-02 | 2018-12-06 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| WO2018231973A1 (en) * | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| WO2019018635A1 (en) | 2017-07-19 | 2019-01-24 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH IMPRESSIVE FAULT |
| EP3668876B1 (en) | 2017-08-18 | 2024-01-24 | Cothera Bioscience, Inc. | Polymorphic form of tg02 |
| CA3074720A1 (en) | 2017-09-05 | 2019-03-14 | Epizyme, Inc. | Combination therapy for treating cancer |
| CA3079260A1 (en) * | 2017-10-17 | 2019-04-25 | Epizyme, Inc. | Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof |
| AU2018354090B2 (en) | 2017-10-23 | 2024-10-24 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
| US12024715B2 (en) | 2017-11-07 | 2024-07-02 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for improved T cells |
| BR112020008325A2 (pt) | 2017-11-14 | 2020-10-20 | Pfizer Inc. | terapias de combinação com o inibidor de ezh2 |
| WO2019226572A1 (en) | 2018-05-23 | 2019-11-28 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity |
| JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのｐｒｃ２サブユニットの阻害 |
| EP3908374A4 (en) | 2019-01-09 | 2022-12-28 | Epitracker, Inc. | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP3934639A4 (en) | 2019-03-04 | 2023-01-11 | Epitracker, Inc. | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN |
| WO2020219606A1 (en) | 2019-04-22 | 2020-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of erk5 inhibitors for treating gliomas in pediatric subjects |
| WO2020216898A1 (en) | 2019-04-24 | 2020-10-29 | Institut Curie | Biomarkers for predicting resistance to cancer drugs |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110835650B (zh) * | 2019-11-21 | 2022-11-25 | 徐州医科大学 | 乳腺癌转移和预后诊断的生物标志物 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN111257405B (zh) * | 2020-03-02 | 2023-08-25 | 中国人民解放军军事科学院军事医学研究院 | 一种利用质谱定量技术对基因毒性物质进行鉴定的方法 |
| US12605387B2 (en) | 2020-07-24 | 2026-04-21 | Secura Bio, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
| WO2022031954A1 (en) * | 2020-08-07 | 2022-02-10 | Athos Therapeutics, Inc. | Ex vivo gastrointestinal biopsy platform to evaluate multi-omic signatures for screening candidate therapeutics |
| US20240350508A1 (en) | 2021-08-25 | 2024-10-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of ezh2 inhibitors for the treatment of aortic valve stenosis |
| WO2023080939A1 (en) | 2021-11-03 | 2023-05-11 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
| KR102816732B1 (ko) | 2021-12-09 | 2025-06-04 | 동의대학교 산학협력단 | 황금 추출물을 유효성분으로 포함하는 티로신 키나아제 억제제 내성 암질환의 예방 및 치료용 약학 조성물 |
| CN119143880A (zh) * | 2024-09-20 | 2024-12-17 | 上海交通大学医学院附属第九人民医院 | 抗ezh2蛋白抗体及其应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0733729A (ja) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法 |
| NZ277556A (en) | 1993-12-27 | 1997-06-24 | Eisai Co Ltd | N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates |
| DE19516776A1 (de) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin-Regulatorgene |
| US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| WO2000018725A1 (en) | 1998-09-30 | 2000-04-06 | The Procter & Gamble Company | 2-substituted ketoamides |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| KR100828982B1 (ko) | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체 |
| US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
| EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
| TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
| JP2004217634A (ja) * | 2002-12-24 | 2004-08-05 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
| EP1663194B1 (en) | 2003-08-26 | 2010-03-31 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
| US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
| CN1286973C (zh) * | 2004-04-12 | 2006-11-29 | 上海第二医科大学附属瑞金医院 | 一种组蛋白甲基转移酶及其制备方法 |
| DE602005017781D1 (de) | 2004-06-01 | 2009-12-31 | Univ North Carolina | Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| KR101347102B1 (ko) | 2005-10-19 | 2014-01-03 | 그뤼넨탈 게엠베하 | 신규한 바닐로이드 수용체 리간드 및 약제를 제조하기 위한이의 용도 |
| EP1951672B1 (en) | 2005-10-21 | 2011-05-25 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| WO2007053480A2 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
| EP1960551A2 (en) | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| AU2006325746A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
| MX2008014616A (es) | 2006-05-15 | 2008-11-28 | Irm Llc | Compuestos y composiciones de tereftalamato, y su uso como inhibidores de integrasa de vih. |
| EP2040711A2 (en) | 2006-05-18 | 2009-04-01 | Amphora Discovery Corporation | 2-oxo-1,2-dihydroquinoline derivatives, compositions, and uses thereof as antiproliferative agents |
| EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | NEUROPROTEKTIVE COMPOSITIONS AND METHOD |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
| WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| DE102007017884A1 (de) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| AU2008337286B2 (en) | 2007-12-19 | 2014-08-07 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
| US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| AU2009279616A1 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
| FR2934995B1 (fr) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique |
| EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| WO2011011366A2 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
| WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
| US8536179B2 (en) * | 2010-05-07 | 2013-09-17 | Glaxosmithkline Llc | Indoles |
| ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| AU2011298987B2 (en) * | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8765792B2 (en) | 2010-12-01 | 2014-07-01 | Glaxosmithkline Llc | Indoles |
| AU2011336272A1 (en) | 2010-12-03 | 2013-06-20 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
| KR102117982B1 (ko) | 2012-04-13 | 2020-06-03 | 에피자임, 인코포레이티드 | 암 치료용 병용 요법 |
-
2011
- 2011-09-12 AU AU2011298987A patent/AU2011298987B2/en not_active Ceased
- 2011-09-12 KR KR1020137009166A patent/KR102061353B1/ko not_active Expired - Fee Related
- 2011-09-12 CN CN201610127289.2A patent/CN105797158B/zh active Active
- 2011-09-12 RU RU2017113351A patent/RU2765155C2/ru active
- 2011-09-12 HU HUE11824247A patent/HUE028977T2/en unknown
- 2011-09-12 RU RU2013115928A patent/RU2618475C2/ru active
- 2011-09-12 KR KR1020227007164A patent/KR102511807B1/ko active Active
- 2011-09-12 ES ES11824247T patent/ES2570380T3/es active Active
- 2011-09-12 CA CA2810998A patent/CA2810998C/en active Active
- 2011-09-12 US US13/230,703 patent/US8895245B2/en active Active
- 2011-09-12 CA CA3176977A patent/CA3176977A1/en active Pending
- 2011-09-12 DK DK11824247.8T patent/DK2614369T3/en active
- 2011-09-12 JP JP2013528375A patent/JP6389036B2/ja active Active
- 2011-09-12 WO PCT/US2011/051258 patent/WO2012034132A2/en not_active Ceased
- 2011-09-12 CN CN201180054109.8A patent/CN103261890B/zh active Active
- 2011-09-12 PL PL11824247T patent/PL2614369T3/pl unknown
- 2011-09-12 KR KR1020197037651A patent/KR102373074B1/ko not_active Expired - Fee Related
- 2011-09-12 EP EP11824247.8A patent/EP2614369B2/en active Active
- 2011-09-12 BR BR112013005806-4A patent/BR112013005806B1/pt active IP Right Grant
-
2013
- 2013-07-23 US US13/949,026 patent/US8691507B2/en active Active
-
2014
- 2014-11-13 US US14/540,977 patent/US9333217B2/en active Active
-
2016
- 2016-04-19 US US15/132,724 patent/US9949999B2/en active Active
- 2016-11-14 JP JP2016221254A patent/JP6496296B2/ja active Active
-
2017
- 2017-12-14 AU AU2017276284A patent/AU2017276284A1/en not_active Abandoned
-
2018
- 2018-03-19 US US15/924,663 patent/US20180271892A1/en not_active Abandoned
- 2018-11-22 JP JP2018218823A patent/JP2019070653A/ja active Pending
-
2020
- 2020-05-19 AU AU2020203245A patent/AU2020203245A1/en not_active Abandoned
- 2020-06-05 US US16/893,851 patent/US20200397812A1/en not_active Abandoned
-
2021
- 2021-06-09 JP JP2021096308A patent/JP2021169450A/ja active Pending
-
2022
- 2022-10-04 AU AU2022242157A patent/AU2022242157A1/en not_active Abandoned
-
2023
- 2023-08-04 JP JP2023127439A patent/JP2023153949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013115928A (ru) | Ингибиторы ezh2 человека и способы их применения | |
| US9045801B2 (en) | Biomarkers for non-hodgkin lymphomas and uses thereof | |
| US11326212B2 (en) | Biomarkers for non-hodgkin lymphomas and uses thereof | |
| JP2007506426A5 (enExample) | ||
| EP2705370A2 (en) | Markers for cancer prognosis and therapy and methods of use | |
| CA2797854A1 (en) | Predictive markers useful in the treatment of fragile x syndrome (fxs) | |
| JP2009502116A5 (enExample) | ||
| GB2484003A (en) | Detection of cancer metastasis | |
| EP2999797A1 (en) | Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy | |
| Yoon et al. | An explorative analysis for the role of serum miR-10b-3p levels in predicting response to sorafenib in patients with advanced hepatocellular carcinoma | |
| JP6241735B2 (ja) | 骨髄異形成症候群または骨髄性腫瘍の評価方法、そのポリペプチド及び抗体、並びにその治療薬若しくは予防薬の候補物スクリーニング方法 | |
| ES2751925T5 (en) | Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor | |
| JP2010502192A5 (enExample) | ||
| US20160312311A1 (en) | Markers for isocitrate dehydrogenase inhibitors | |
| JP2015506665A5 (enExample) | ||
| Desjardins et al. | Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high‐risk non BRCA1/2 French Canadian breast and ovarian cancer families | |
| Morais et al. | Involvement of Merkel cell polyomavirus in the etiology and pathogenesis of Merkel cell carcinoma: A systematic review | |
| WO2005007849A1 (ja) | アルキル化薬感受性を上昇させる方法 | |
| Zhu et al. | progression in KRAS p. G12D-mutant colorectal cancer by binding to DHX15 | |
| Kwok et al. | Drug addiction mutations unveil a repressive methylation ceiling in EZH2-mutant lymphoma | |
| Suzuki et al. | DNA and Histone Methylation in Colon Cancer: Its Biological Impact and Clinical Implications | |
| KR101766005B1 (ko) | 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법 | |
| KR101805977B1 (ko) | 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법 | |
| WO2023220648A2 (en) | Compositions and methods for detecting and treating tumors and/or cancers associated with braf and/or map2k1 variants | |
| Crean | Role of ISG15 in cancer |